# HS-IT201 Injection in the Treatment of Advanced Solid Tumors

> **NCT06613152** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Qingdao Sino-Cell Biomedicine Co., Ltd.** · enrollment: 9 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** HS-IT201 Injection

## Key facts

- **NCT ID:** NCT06613152
- **Lead sponsor:** Qingdao Sino-Cell Biomedicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-10
- **Primary completion:** 2026-10
- **Final completion:** 2028-10
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2024-09-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06613152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06613152, "HS-IT201 Injection in the Treatment of Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06613152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*